ArticleBiochemistry and biophysics reports2025
New breast cancer marker BF-09 is overexpressed in tumor extracts and secreted in serum.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CA 15-3 and CA 27-29 are widely used serum biomarkers for breast cancer with limited utility due to low sensitivity in early-stage disease. This study details the discovery of BF-09, a new breast cancer marker with potential for wider application. Method: Antibodies were screened against tumor biopsy extracts (n = 115) relative to non-cancer (n = 190) specimens using an immunoscreening array. Western blot was done to determine the molecular weight of the antibody target and test secretion in cell culture medium. A sandwich ELISA was developed and tested on mouse xenograft serum to confirm in vivo secretion. A preliminary set of cancer (n = 14) and non-cancer (n = 13) human serum samples was similarly tested to confirm the biomarker could be measured in human blood. HuProt Human Protein Array was used for target protein identification. Results: BF-09 antibody was selected for further study because its protein target was elevated in both early and late-stage cancer extracts (p < 0.05). On Western blot, BF-09 antibody reacted against a protein band of around 15 kDa. ELISA results confirmed that the biomarker was secreted in both mouse and human serum in quantifiable amounts. BF-09 protein had higher median concentration in serum of cancer patients (p < 0.0001) compared to non-cancer patients. Phage display and HuProt array revealed the protein target as SAGA-associated factor 29. Conclusion: Due to its elevated presence in early-stage tumor tissue and its measurable secretion into serum, BF-09 is a promising breast cancer marker for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.